Fluvoxamine treatment of obsessivecompulsive symptoms in schizophrenic patients: an add-on open study
The DOI matches its Crossref record.
Abstract
Obsessive-Compulsive (OC) symptoms are observed in a substantial proportion of schizophrenic patients and pose a significant therapeutic challenge. Based on findings of the benefit of the anti-obsessive agent clomipramine, we designed an open-label study to examine the effect of adding the serotonin-selective reuptake inhibitor (SSRI) fluvoxamine to the ongoing antipsychotic regimen of schizo-obsessive patients. The study population consisted of ten neuroleptic-stabilized chronic schizophrenic patients with OC symptoms. Fluvoxamine (up to 150 mg/day) was added to the ongoing antipsychotic treatment, which remained unchanged for the entire 12-week trial period. The patients were evaluated before the trial and at weeks 1, 2, 4, 6, 8 and 12 (end point) with the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), the Schedule for Assessment of Positive Symptoms and the Schedule for Assessment of Negative Symptoms. The results showed a significant improvement in obsessions (P < 0.02) (but not compulsions) and both positive (P < 0.01) and negative (P < 0.05) schizophrenic symptoms. By the end of the trial, three patients showed a more than 50% reduction in the Y-BOCS score, with complete amelioration of the OC symptoms in one of them. Three patients were dropped from the study during the first 4 weeks, two because of aggressiveness and one because of psychotic exacerbation. No exacerbation or new onset of extrapyramidal side-effects (EPS), as measured by the Barnes Akathisia Scale (BARS) and the Simpson-Angus Scale (SAS), was noted during the course of the trial and there were no other significant clinical side-effects of fluvoxamine addition. We conclude that fluvoxamine may be an effective adjunctive agent in some schizo-obsessive patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Anxiety in Patients with Schizophrenia: Epidemiology and Management
Temmingh, H., & Stein, D. J. (2015) · CNS Drugs · doi:10.1007/s40263-015-0282-7 · Cited by 173
Fonseka, T. M., Richter, M. A., & Müller, D. J. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0510-8 · Cited by 93
The neuropsychology of the schizo-obsessive subtype of schizophrenia: a new analysis
Patel, D. D., Laws, K. R., Padhi, A., Farrow, J. M., Mukhopadhaya, K., Krishnaiah, R., & Fineberg, N. A. (2010) · Psychological Medicine · doi:10.1017/s0033291709991255 · Cited by 82
“…0.5 to 59.2% both in firstepisode and in chronic schizophrenia (Bland et al. 1987 ; Karno et al. 1988 ; Berman et al. 1995 ; Eisen et al. 1997 ; Poyurovsky et al. 1999a, 2000, 2003, 2006 ; Bermanzohn et al. 2000 ; Kruger et al. 2000 ; Niehaus et al. 2005 ; Mukhopadhaya et al. 2009) and for OCS…”
BackgroundInfluential
Metadata
- Authors
- Poyurovsky, M., Isakov, V, Hromnikov, S., Modai, I., Rauchberger, B., Schneidman, M., & Weizman, A.
- Venue
- International Clinical Psychopharmacology
- Published
- 1999-03
- Volume
- 14
- Issue
- 2
- Pages
- 95-100
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2117944358
- Cited by
- 55
- References
- 0
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fluvoxamine treatment of obsessivecompulsive symptoms in schizophrenic patients: an add-on open study. https://app.cochat.ai/papers/10.1097/00004850-199903000-00006
- The paper
- Poyurovsky, M., Isakov, V, Hromnikov, S., Modai, I., Rauchberger, B., Schneidman, M., & Weizman, A. (1999). Fluvoxamine treatment of obsessivecompulsive symptoms in schizophrenic patients: an add-on open study. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-199903000-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.